Sera Prognostics, Inc. Announces Publication of Health Economic Analysis Supporting Pretrm Test-And-Treat Strategy to Improve Maternal and Infant Health
September 14, 2021 at 08:00 am EDT
Share
Sera Prognostics Inc. announced the publication of a rigorous clinical and economic analysis using actual claims data from a broad population of Anthem affiliated health plans to assess the potential value of the PreTRM® test-and-treat strategy. The study conservatively modeled the PreTRM® strategy, consisting of testing and proactive evidence-based interventions, within Anthem claims data from individual and employer-sponsored plans, and showed both improved neonatal outcomes and reduced immediate and long-term treatment costs associated with premature birth, when compared to routine care. These results were published in the peer-reviewed journal ClinicoEconomics and Outcomes Researchin an article entitled “Cost-Effectiveness of a Proteomic Test for Preterm Birth Prediction." The study analysis was conducted by Sera in partnership with HealthCore, using claims data of more than 40,000 pregnant women and infants who were members of individual and employer-sponsored Anthem health plans. The analysis evaluated the PreTRM® test-and-treat strategy by modeling the application of the PreTRM® test during weeks 19 or 20 of pregnancy, and assessed the benefit of proactive interventions consisting of more intensive case-management and monitoring, as well as pharmacologic interventions for women identified as higher-risk by the test, whereas usual care was assumed for any women without higher PreTRM® risk. Key findings of the analysis include: 20% reduction in preterm birth <37 weeks’ gestation; 33% reduction in births <32 weeks’ gestation; 10% reduction in neonatal intensive care admissions; 7% reduction in overall hospital length-of-stay; $863 net savings ($1,608 gross savings) per pregnant woman, a $54 million reduction in total costs over the study population. Based on the study’s estimated net cost savings to the healthcare system of $863 saved per pregnant woman, the authors estimate that more than $850 million could be saved annually in U.S. individual and employer-sponsored health plans, assuming full uptake of the test-and-treat strategy. This is based on an assumption of approximately 4 million births per year, of which approximately 50% occur in women with such commercial health insurance, and further assuming at least half have no evident risk factors for preterm birth.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant motherâs risk of delivering spontaneously before 37 weeksâ gestation.
Sera Prognostics, Inc. Announces Publication of Health Economic Analysis Supporting Pretrm Test-And-Treat Strategy to Improve Maternal and Infant Health